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ABSTRACT 
Background: Drug allergy interaction (DAI) alerts are generated when a known adverse 
sensitivity-inducing substance is prescribed. A recent study at our institution showed that 
providers overrode most DAI alerts, including those that warned against a potentially life-
threatening ‘anaphylaxis.’ 
Objective: To determine the rate of anaphylaxis overrides, the reasons for these overrides, 
whether the overrides were appropriate, and if harm occurred from overrides. 
Methods: All DAI alerts, with a reaction of ‘anaphylaxis’, were analyzed for inpatients and 
outpatients within our health-system between January 2009 and December 2011. Only alerts that 
were triggered by ‘definite’ matches (i.e., same ordered medication as documented allergen) 
were included. A total of 202 inpatient and 16 outpatient alerts met inclusion criteria, and 
respective charts were reviewed to assess the appropriateness of overrides and potential harm 
induced by the drug. 
Results: The rate of overrides for ‘definite’ anaphylaxis DAI alerts was high (inpatient: n=93, 
46.0%; outpatient: n=11, 68.8%) but appropriate for most overrides in the inpatient (n=78, 
83.9%) and outpatient setting (n=11, 100%). Desensitizations accounted for the majority of 
appropriate overrides (n=65, 73.0%). The most common override reasons in the inpatient and 
outpatient setting were ‘administer per desensitization protocol’ (n=64, 82.1%) and ‘patient does 
not have this allergy’ (n=7, 63.6%), respectively, and all of the latter were removed from the 
patients’ records. No harm was associated with appropriate or inappropriate overrides in either 
setting, particularly because many drugs were not administered eventually. 
Conclusions: Overrides of ‘definite’ anaphylaxis DAI alerts were common but a large fraction 
was appropriate. Most overrides were due to desensitizations and removal of these alerts from 
order sets would substantially reduce the alert burden. Allergy reconciliation for patients could 
further improve the specificity of potentially critical decision support.    
 
  
BACKGROUND 
Adverse drug reactions (ADRs) are responses to medications at normal human doses, 
which are noxious and unintended.1 Drug allergies represent one type of ADRs; clinically both 
sensitivities and allergies are often reported as allergies by clinicians. However, true allergies are 
immunologically-mediated hypersensitivity reactions that can range from mild reactions (e.g. 
itching) to severe reactions, such as anaphylaxis.2 These reactions account for less than 10% of 
ADRs.3 A large epidemiologic study of patient-reported allergy within our health-system found 
that 35.5% of our patients had documentation of at least one allergy, with 54.7% of this 
population only having one allergy documented.4 Anaphylaxis, which is a sudden onset of a life-
threatening systemic or hypersensitivity reaction, has been estimated to have a lifetime risk of 
1.6% in the general population.5 The true incidence of medication-induced anaphylaxis is 
unknown, with variability based on medications, patient risk factors, and populations.3 
Antibiotics such as penicillin represent a common documented allergen but most lack of 
objective evidence of reactions (i.e. immunologic testing).5 To deliver appropriate decision 
support in electronic health records (EHRs), it is important to accurately determine what the 
reaction was, to assess whether or not it appeared to be a true allergy, and to assess whether or 
not anaphylaxis was present.6 
Nearly all EHRs include ‘allergy’ modules for documentation of a patient’s reported and 
observed reactions to medications, and this is required for EHRs to be certified in the U.S.7 
However, not all of these EHRs separate anaphylaxis from other types of reactions. A recent 
study conducted at our institution showed that the majority of reported reactions was commonly 
entered as “unknown.”8  
  Given the severity of anaphylaxis, it would be expected that such CDS alerts would 
rarely be overridden; however, data suggest otherwise, with data identifying an override rate of 
approximately 80%.9 Some of the reasons for this include poor allergy record stewardship and 
alert fatigue.8-10 In this study, we assessed 1) how many alerts related to anaphylaxis were 
present and how often they were overridden, 2) the reasons that providers overrode them, 3) the 
appropriateness of these overrides, and 4) harm that occurred upon administration of an 
overridden alert. 
METHODS 
Drug-allergy interaction (DAI) alerts with a documented reaction of ‘anaphylaxis’ in a 
patient’s medical record were included from January 2009 to December 2011 for inpatients at 
Brigham and Women’s Hospital (BWH) and for outpatients from primary care practices 
affiliated with Partners HealthCare. Partners HealthCare is an integrated healthcare delivery 
system in the greater Boston area that was founded by BWH and Massachusetts General Hospital 
(MGH), both large academic tertiary care centers. A patient’s allergy information is entered in 
the EHR, which is then stored in a health-system wide repository, allowing for longitudinal 
record access.11 Only drug allergies identified as a ‘definite’ match between the ordered 
medication and the documented allergen were included in this analysis. These alerts were chosen 
given the highly sensitive mapping of medication cross-reactivity which has been identified in 
the literature.8  
When a medication is ordered, it is compared to a patient’s reported allergies using a 
commercial knowledge base (First DataBank, South San Francisco, CA). If there is a potential 
interaction between this documentation and the ordered medication, a DAI alert fires and is 
displayed on the provider’s computer screen. These alerts are interruptive, requiring a provider to 
either cancel the order or to override the alert. In the inpatient setting, providers can see the 
documented reaction, reason for a previous override of this alert for a patient, and input a free-
text reason for overriding this alert (Figure 1). Pharmacists and nurses can then see the DAI alert 
for those that were overridden, to allow for double-checking the order upon verification and 
administration. In the outpatient setting, providers can see the documented reaction and choose 
to keep the order through one of the following mechanisms, 1. Choose “Patient does not have 
this allergy, will D/C pre-existing allergy” or 2. Choose a coded reason for override (i.e., no 
reasonable alternatives) or 3. Input a free-text reason for the override (Figure 2). 
Data included the ordered medication and the documented allergen in the patient’s 
medical record that triggered the DAI alert, and the documented reason for override. We also 
collected serum tryptase levels to help with confirmation of actual anaphylaxis to the 
documented allergen near the time of allergy documentation, if available.5 The appropriateness 
of the override was assessed through detailed chart review according to a priori criteria 
developed by a multidisciplinary group. The criteria covered the evaluation of the documented 
override reason, evidence of previous tolerance of the medication, and if the medication was 
ordered for a desensitization by an allergy specialist. In evaluating the override coded reason 
‘Physician aware,’ we evaluated documented notes in the patient record demonstrating that the 
medical team was actually aware that the patient had a medication ordered, despite a documented 
reaction of ‘anaphylaxis’, or if the patient had previously tolerated the medication. 
RESULTS 
A total of 1,851 inpatient and 216 outpatient DAI alerts with a reaction of ‘anaphylaxis,’ 
were included. These overrides were obtained from 499 inpatient encounters with a median 
number of 1 alert per encounter (IQR 1, 4), and 140 outpatient visits with a median number of 1 
alert per visit (IQR 1, 2). The override rates for all alerts were 68.7% and 59.3% in the inpatient 
and outpatient settings, respectively. Demographics of patients are detailed in Table 1. 
After reviewing alert content for non-‘definite’ matches, a total of 218 (10.5%) alerts 
remained (inpatient, n=202, 10.9%; outpatient, n=16, 7.1%). The largest category of exclusion 
was that of antimicrobials and cross-sensitivity between the allergen and the ordered medication 
(n=795, 43.0%). The group of ‘definite’ overrides were derived from 107 inpatient encounters 
with a median number of 1 alert per encounter (IQR 1, 2) and 13 outpatient visits with a median 
number of 1 alert per visit (IQR 1, 1). The rate of ‘definite’ anaphylaxis DAI alert overrides were 
46.0% (n=93) and 68.8% (n=11) in the inpatient and outpatient settings, respectively. The most 
common allergens associated with medication actions or overrides are detailed in Table 2 and 
Table 3 for the inpatient and outpatient settings, respectively. We were unable to obtain serum 
tryptase levels for any patient at the time of allergy documentation to help with confirmation of 
anaphylaxis to the documented allergen. This was due to no serum tryptase being ordered on the 
day of allergy documentation. 
In evaluating the 93 overrides in the inpatient setting, aspirin was the most common 
allergen (n=13, 14.0%), with chemotherapy agents and antimicrobials the most common 
medication classes of allergens overridden (n=49, 52.7% and n=9, 9.7%, respectively). A total of 
78 of the 93 overrides were identified to have been appropriate overrides (83.9%). Of the 78 
appropriately overridden alerts, 67 resulted in medication administration (85.9%), with a median 
number of 1 administration (IQR 1, 1). Only 2 of the appropriately overridden alerts resulted in 
eventual discontinuation of the allergen (2.6%), which was not accomplished during the patient’s 
stay. The override reasons for these cases were “Pt allergic to IV contrast not Readicat” and 
“Physician aware.” Of the appropriate overrides that resulted in medication administration, 57 
had a documented override reason of ‘desensitization’ (85.1%). Only 1 of these was not ordered 
via a desensitization protocol (1.8%). No patient harm was found to have occurred following 
medication administration of the non-desensitization orders. Of the 15 inappropriately 
overridden DAI alerts in the inpatient setting, “Physician aware” was the most common reason 
for the override (n=6, 40.0%), with “Low risk cross sensitivity” being the second most common 
(n=3, 20.0%). Twelve of the inappropriately overridden alerts did not pass order verification by 
the pharmacist either due to pharmacist intervention or from the provider subsequently 
discontinuing the order after order entry. The remaining 3 overrides were for prochlorperazine 
suppositories ordered as needed, which the patient was never administered. 
In evaluating the 11 overrides in the outpatient setting, all were identified to be 
appropriately overridden (100%). Aspirin was the most commonly overridden allergen (n=5, 
55.5%), followed by morphine (n=2, 22.2%). The most common reason for an appropriate 
override was “Patient does not have this allergy – will D/C pre-existing allergy.” In all of these 
cases, the allergen was removed from the patient’s medical record. 
DISCUSSION 
We assessed how often anaphylaxis was presented as the potential reaction when allergy 
warnings were displayed, how often warnings were overridden, and what the clinical 
consequences of these overrides were for the patient. We found that while overrides were 
common, over 80% of overrides were appropriate, and we found no overrides that induced harm 
including inappropriately overridden alerts as no medication administration occurred from these 
alerts. Many of these warnings occurred in the context of desensitization protocols that usually 
require additional knowledge and attention by specialists. Overall, these data suggest that while 
anaphylaxis can be very serious, clinicians in this institution appeared appropriately concerned 
about it and were making good clinical decisions.  
Overrides of DAI alerts have been identified as common in previous studies, with rates 
ranging from 80% to 96%.8-11 However, according to our data, anaphylaxis seems to be a rare 
type of allergic reaction. Override rates for anaphylaxis alerts for any DAI (i.e. not specific to 
‘definite’ matches) were previously found to be 81.9% and 77.0% in the inpatient and outpatient 
settings, respectively.8 These findings differ from ours, which were higher in the outpatient 
setting. On one hand, it might be expected that override rates of ‘anaphylaxis’ alerts would be 
lower in the outpatient setting as patients are less closely monitored. On the other hand, the 
override rate might be higher given the greater familiarity of patients to their primary care 
providers, whereas inpatient providers would be less likely to be familiar with a patient’s past 
medical history and therefore may be less likely to override alerts, except in the cases of 
medication desensitization. 
In terms of the documented override reason given that only ‘definite’ alerts were 
considered, the alerts with an override reason of ‘Low risk cross sensitivity’ were an interesting 
finding. This override reason may have resulted from alert fatigue. Since, a significant portion of 
the inpatient and outpatient overrides (73.0% of all overrides) were triggered in the context of 
desensitization protocols (inpatient: 68.8%; outpatient: 9.1%), it should be considered to 
suppress allergy alerts from these order sets to reduce the alert burden for providers.  
In evaluating the appropriateness of these DAI overrides, we found a very high 
proportion to be appropriately overridden. These results correspond to other studies which found 
an appropriateness rate of DAI alerts of 96.0% and 70.9% in the inpatient and outpatient settings, 
respectively.8 Of greater significance than the appropriateness of the override is whether patients 
were actually harmed by CDS alerts overrides. In a study focused on DAI, 22 potential adverse 
drug events (ADEs) were found over a 3-month period.10 A total of 19 were confirmed to be 
ADEs via a physician panel discussion, of which 10 (52.6%) were identified to be classified as 
‘significant’ with 9 classified as serious ADEs. However, none of these ADEs were identified to 
have been preventable. In our study, no harm occurred as a result of these overrides, which is of 
note as there was no difference between appropriately and inappropriately overridden 
anaphylaxis alerts. This was because no inappropriately overridden alerts resulted in medication 
administration to the patient.   
Similar to our study, the most common reason for overriding these DAI alerts in another 
publication was that the patient had previously tolerated the medication (50.9%).9 However, data 
suggest that a patient’s allergy list is updated in only 16.7% of the time, which is particularly 
striking if “has previously tolerated” or “patient does not have this allergy”  was entered by 
providers.10 The authors suggest that this may be due to reliance on patient self-report, infrequent 
updating of allergies, or the numerous locations where allergies may be documented in a 
patient’s medical record.   
Our study has several limitations. This study was done within one health-system and 
therefore the results may not be generalizable to other systems or settings. Although this was 
completed in a legacy, homegrown EHR, we do not expect the findings of this study to differ 
from what we would find in our current commercial EHR, as the same knowledge base is being 
used. We were not able to validate whether the documented anaphylaxis in these DAI alerts was 
a true reaction through lab or testing information. Our study suggests that documentation of 
‘anaphylaxis’ is not very specific, given that a common override reason was that the patient 
actually did not have this allergy. In the case in which a provider overrides an alert due to the 
perception of a false-negative (i.e. override of an alert in a patient with actual anaphylaxis), there 
is a risk of anaphylaxis recurrence in approximately one-third of patients.12 Recommendations 
for improved DAI include increased accuracy of allergy documentation, with reconciliation and 
stewardship of a patient’s documented allergic reactions, and the creation of algorithms designed 
to increase the specificity of allergy documentation by identifying likely causes of the underlying 
reaction.6,13  
Inappropriate drug allergy alerts at best can waste clinicians’ time, and so it is very 
important that the information contained in patients’ drug allergy lists and the clinical evidence 
on drug cross-reactivity in the decision support systems is always up to date. All EHRs should 
collect information on allergic reactions, with anaphylaxis being a particularly important 
reaction. It might be helpful in the future to ask providers why they believe the reaction was 
anaphylaxis to enable better downstream decision-making. Additionally, removal of these alerts 
may be beneficial when a desensitization protocol is ordered. 
CONCLUSION 
We found a high rate of overrides of warnings against definite anaphylaxis, but a high 
proportion of these overrides were judged to be appropriate in both inpatient and outpatient 
settings. Desensitization protocols should be modified to bypass these warnings. Improved 
patient allergy reconciliation may also be beneficial in reducing the alert burden associated with 
these potentially critical alerts.  
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TABLES 
Table 1. Patient demographics 
 Inpatient (n=107) Outpatient 
(n=13) 
Age, y, median (IQR) 63 (49, 72.5) 66 (44, 81) 
Female, n (%) 84 (78.5) 11 (84.6) 
Race, n (%) 
 White 86 (80.4) 10 (76.9) 
 Black 9 (8.4) 1 (7.7) 
 Hispanic 3 (2.8) 1 (7.7) 
 Asian 1 (0.9) 0 (0) 
 Other 8 (7.5) 1 (7.7) 
Number of documented allergies, n, median (IQR) 4.0 (2.0, 7.0) 6.0 (4.0, 7.0) 
 
  
Table 2. Documented override reason or action with most common medications by override 
reason for inpatient alerts 
Cancel order, n (% of total) 109 (54.0) 
 Prochlorperazine, n (%) 21 (19.3) 
 Ondansetron, n (%) 13 (11.9) 
 Acetaminophen, n (%) 8 (7.3) 
Administer per desensitization protocol, n 
(% of total) 
64 (31.7) 
 Aspirin, n (%) 13 (20.3) 
 Paclitaxel, n (%) 13 (20.3) 
 Carboplatin, n (%) 12 (18.8) 
Patient has taken previously without 
allergic reaction/patient has tolerated 
previously, n (% of total) 
10 (5.0) 
 Prochlorperazine, n (%) 3 (30.0) 
 Ipratropium and albuterol, n (%) 2 (20.0) 
 Other, n (%) 5 (50.0) 
Physician aware, n (% of total) 7 (3.5) 
 Ciprofloxacin, n (%) 2 (28.6) 
 Ondansetron, n (%) 2 (28.6) 
 Other, n (%) 3 (42.8) 
Other, n (% of total) 12 (5.8) 
 Oxycodone, n (%) 3 (25.0) 
 Other, n (%) 9 (75.0) 
 
  
Table 3. Documented override reason or action with most common medications by override 
reason for outpatient alerts 
Cancel order, n (% of total) 5 (31.3) 
 Azithromycin, n (%) 3 (60.0) 
 Ibuprofen, n (%) 1 (20.0) 
 Nitrofurantoin, n (%) 1 (20.0) 
Patient does not have this allergy, will D/C 
pre-existing allergy, n (% of total) 
7 (43.8) 
  Aspirin, n (%) 4 (57.1) 
  Butalbital-acetaminophen-caffeine, n (%) 1 (14.3) 
  Levofloxacin, n (%) 1 (14.3) 
  Tocilizumab, n (%) 1 (14.3) 
Patient has taken previously without 
allergic reaction/patient has tolerated 
previously, n (% of total) 
3 (18.8) 
  Morphine, n (%) 2 (66.7) 
  Insulin lispro, n (%) 1 (33.3) 
Desensitization, n (% of total) 1 (6.1) 
  Aspirin, n (%) 1 (100) 
 
  
FIGURES 
 
Figure 1. Drug-allergy interaction alert in the inpatient setting for a patient with anaphylaxis to 
codeine 
 
Figure 2. Drug-allergy interaction alert in the outpatient setting for a patient with anaphylaxis to 
codeine 
 
